Ni isalẹ ni akopọ ojoojumọ ti awọn ọna asopọ si awọn iroyin SPAC tuntun ati awọn agbasọ ọrọ ti o pejọ kọja wẹẹbu. 

Latest SPAC News: Hong Kong considers allowing SPAC listings, Redbox Entertainment acquires Vendetta distribution rights, and EQRx announces presentation of phase 3 data

Hong Kong Proposes SPAC Listings, But Only for Professional Investors

Hong Kong Exchanges & Clearing has outlined plans to allow the listing of blank-check corporations whose global popularity has soared over the past year, just two weeks after regional rival Singapore greenlit the float of such entities.

HKEX, however, proposes to take a more cautious approach than Singapore or the U.S.

Under the proposal offer for public comment on Friday, only institutional investors or individuals with a portfolio worth at least 8 million Hong Kong dollars ($1.03 million) would be allowed to invest in Hong Kong SPACs.

KỌRỌ

Redbox Entertainment Acquires U.S. Distribution Rights to Action Thriller Movie Vendetta

Redbox Entertainment, the original content division of Redbox, today announced it has acquired U.S. distribution rights to the action-thriller movie Vendetta.  The film will premiere in 2022 and is expected to have a limited theatrical run and be available day-and-date On Demand.

Redbox recently announced a definitive agreement to combine with Seaport Global Acquisition Corp. (NASDAQ:SGAM).

KỌRỌ

EQRx Announces Presentation of Phase 3 Data Demonstrating a Progression-Free Survival Benefit 

EQRx, a new type of pharmaceutical company committed to developing and delivering important new medicines to patients at radically lower prices, today announced a late-breaking mini oral presentation of data from its partner CStone Pharmaceuticals’ Phase 3 GEMSTONE-301 study at the European Society for Medical Oncology (ESMO) Congress 2021.

GEMSTONE-301 is a placebo-controlled Phase 3 trial evaluating the efficacy and safety of the anti-PD-L1 antibody sugemalimab as consolidation therapy in patients with locally advanced/unresectable Stage III non-small cell lung cancer (NSCLC) without disease progression after concurrent or sequential chemoradiotherapy.

In August 2021, EQRx announced a proposed combination with CM Life Sciences III (NASDAQ: CMLTU) to accelerate growth.

KỌRỌ